UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.
Date
2023-09
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Price, Meghan J, Annee D Nguyen, Jovita K Byemerwa, Jasmine Flowers, César D Baëta and C Rory Goodwin (2023). UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology. Oncotarget, 14(1). pp. 843–857. 10.18632/oncotarget.28514 Retrieved from https://hdl.handle.net/10161/33174.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Annee Nguyen
Annee is a graduate student in Duke's Department of Pharmacology, a joint program with Molecular Cancer Biology. She is excited to identify therapeutic molecules and elucidate therapeutic mechanisms of antitumor efficacy that may also target secondary comorbid conditions, such as pain or neurological deficits. She is passionate about scientific education and communication and hopes to remain in academia with the goal of cultivating the next generation of scientists.
In 2017, Annee graduated from the University of California, San Diego, from Warren College, with a Bachelor of Science in Human Biology (double minoring in Psychology and Theatre) as magna cum laude and as part of the Sigma Chapter of the Phi Beta Kappa Society and obtained a contiguous Master of Science in Biology in 2018, concentrating in Neuropathology and Scientific Communication.
Since 2014, her prior research experience includes working with various preclinical models of peripheral neuropathy (with Dr. Nigel Calcutt and Dr. Christina Sigurdson of UC San Diego’s Department of Pathology), equine and murine models of neuroaxonal dystrophy (with Dr. Carrie Finno of UC Davis’s School of Veterinary Medicine), and CNS tumor preclinical models of recurrent glioblastoma and spine tumors and metastases at Duke University Medical Center with Dr. Rory Goodwin of the Duke Center for Brain and Spine Metastasis and the Department of Neurosurgery. In each lab, she sought to identify therapeutics that could prevent, reverse, or abate the neurodegenerative diseases of focus and explored mechanisms of disease development and therapeutic impact. Throughout her experiences, Annee has continually focused on developing projects driven by clinical impact and focused on taking science from bench to bedside and back.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.